Summary
AleloPharma Inc. proposes to develop an ultra-precision liquid biopsy diagnostic test for detecting ALK translocation variants in ALK-positive non-small cell lung cancer (NSCLC) patients using their AleloMAX molecular detection system.
Ultra-precision diagnostics for ALK+ non-small cell lung cancer
US · IL
NIH RePORTER
grant
awarded
#nih-1R43CA298267-01A1
What they want
The project aims to develop an ultra-specific and ultra-sensitive molecular detection platform for EML4-ALK gene fusion translocations in ALK+ NSCLC, probing fusion RNAs using synthetic, in vitro-transcribed mRNAs. A clinical proof-of-principle study will then demonstrate the AleloMAX-ALK platform's resolution power and limit-of-detection using plasma- and/or blood-derived nucleic acid samples from ALK+ NSCLC patients, ALK- NSCLC patients, and healthy control volunteers. The ultimate goal is to develop a diagnostic kit for use in clinical labs and for a Phase II study.
Deliverables
- Ultra-specific and ultra-sensitive molecular detection platform for EML4-ALK gene fusion translocations
- Liquid biopsy test kit for detecting ALK translocation variants
Technical requirements
- AleloMAX high-dimensional molecular detection system
- 1-absolute copy per reacting assay limit-of-detection (LOD)
Risks & flags
Incumbent: AleloPharma Inc.
Market context
inferred from NAICSProfessional, Scientific & Technical Services
NAICS 541714
- US market size
- $2.0T
- Typical award
- $25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP
Sector-level estimate — full code lookup not yet in catalog.
